Phenotype-based single cell sequencing identifies diverse genetic subclones in CD133 positive cancer stem cells

Dong-Wook Min,Hwang-Phill Kim,Jinhyun Kim,Xianyu Wen,Sungsik Kim,Young-Won Cho,Yoojoo Lim,Sang-Hyun Song,Sae-Won Han,Sunghoon Kwon,Gyeong Hoon Kang,Tae-You Kim

DOI: https://doi.org/10.1016/j.bbrc.2020.09.005

2021-06-18

Abstract:Tumor heterogeneity is one of the ongoing huddles in the field of colon cancer therapy. It is evident that there are countless clones which exhibit different phenotypes and therefore, single cell analysis is inevitable. Cancer stem cells (CSCs) are rare cell population within tumor which is known to function in cancer metastasis and recurrence. Although there have been trials to prove intra-tumoral heterogeneity using single cell sequencing, that of CSCs has not been clearly elucidated. Here, we articulate the presence of heterogeneous subclones within CD133 positive cancer stem cells through single cell sequencing. As a proof of principle, we performed phenotype-based high-throughput laser isolation and single cell sequencing (PHLI-seq) of CD133 positive cells in a frozen tumor tissue obtained from a patient with colorectal cancer. The result proved that CD133 positive cells were shown to be heterogeneous both in copy number and mutational profiles. Single cancer stem cell specific mutations such as RNF144A, PAK2, PARP4, ADAM21, HYDIN, KRT38 and CELSR1 could be also detected in liver metastatic tumor of the same patient. Collectively, these data suggest that single cell analysis used to spot subclones with genetic variation within rare population, will lead to new strategies to tackle colon cancer metastasis.